SEARCH

SEARCH BY CITATION

References

  • 1
    Sakamoto J, Hamada C, Kodaira S, Nakazato H, Ohashi Y. Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials. Jpn J Clin Oncol 1999; 29: 7886.
  • 2
    Sakamoto J. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22: 48492.
  • 3
    Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990; 48: 38195.
  • 4
    Danenberg PV. Thymidylate synthetase a target enzyme in cancer chemotherapy. Biochem Biophys Acta 1977; 473: 7392.
  • 5
    Leichman CG, Lenz HJ, Danenberg PV. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15: 32239.
  • 6
    Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Demura H, Sasano H. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1995; 1: 153743.
  • 7
    Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 13227.
  • 8
    Ochiai T, Sugitani M, Nishimura K, Noguchi H, Watanabe T, Sengoku H, Kihara A, Okano M. Correlation between 5-fluorouracil (5-FU) sensitivity as measured by collagen gel droplet embedded culture drug sensitivity test (CD-DST) and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer. Gan To Kagaku Ryoho 2001; 28: 6617.
  • 9
    Ochiai T, Sugitani M, Nishimura K, Noguchi H, Okada T, Oouchi M, Yamada M. Prognostic impact of orotate phosphoribosyl transferase (OPRT) activity in resectable colorectal cancers (CRC) treated by 5-FU-based adjuvant chemotherapy. Proc ASCO 2004; 22: 3574.
  • 10
    Halvorsen TB, Seim F. Degree of differenciation in colorectal adenocarcinomas: a multivariate analysis of the influence on survival. J Clin Pathol 1988; 41: 5327.
  • 11
    Kanemitsu Y, Kato T, Hirai T, Yasui K, Morimoto T, Shimizu Y, Kodera Y, Yamamura Y. Survival after curative resection for mucinous adenocarcinoma of the colorectum. 2003; 46: 1607.
  • 12
    Laskin JD, Evans RM, Slocum HK, Burke D, Hakala MT. Basis for natural variation in sensitivity to 5-Fluorouracil in mouse and human cells in culture. Cancer Res 1979; 39: 38390.
  • 13
    Diasio RB. Familial deficiency of dihydropyridine dehydrogenase: biochemical bases for familial pyrrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81: 4751.
  • 14
    Harris BE. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197201.
  • 15
    Spears CP, Shahinian AH, Corbetto TH. In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and resistant murine colon adenocarcinomas. Cancer Res 1982; 42: 4506.
  • 16
    Miller R, Siegmund D. Maximally selected χ2 statistics. Biometrics 1982; 38: 10116.
  • 17
    Halpern J. Maximally selected χ2 statistics for small samples. Biometrics 1982; 38: 101723.
  • 18
    Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, Sugihara K, Sasaki Y, Hirayama R. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003; 89: 148692.
  • 19
    Fujii R, Seshimo A, Kameoka S. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 2003; 8: 7278.
  • 20
    Hoelzer D, Gökbuget N, Ottmann O, Pui C-H, Relling MV, Appelbaum FR, van Dongen JJM, Szczepanski T. Acute lymphoblastic leukemia. Hematology 2002; 2002: 162192.
  • 21
    Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, Kinzler KW, Vogelstein B, Hamilton SR. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331: 21321.
  • 22
    Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 26407.
  • 23
    Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G,Jr, Jessup JM, Loda M, Summerhayes IC. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996; 335: 172732.
  • 24
    Bauer KD, Lincoln ST, Vera-Roman JM, Wallemark CB, Chmiel JS, Madurski ML, Murad T, Scarpelli DG. Prognostic implications of proliferative activity and DNA aneuploidy in colonic adenocarcinomas. Lab Invest 1987; 57: 32935.
  • 25
    Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschek T, Nordenskjold B. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992; 340: 136973.
  • 26
    Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 6977.
  • 27
    Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O'Dwyer PJ, Muro K, Yamada Y, Boku N, Nagashima F, et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 2004; 22: 346674.